查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1657591

DNA 定序市场 - 全球产业规模、份额、趋势、机会和预测，按产品类型、技术、应用、最终用户、地区和竞争细分，2020-2030 年预测

DNA Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Technology, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球 DNA 定序市场价值为 152.2 亿美元，预计到 2030 年将达到 467.2 亿美元，复合年增长率为 20.53%。由于技术进步、基因组学应用的不断增加以及精准医疗需求的不断增长，全球 DNA 测序市场经历了显着增长。定序技术，尤其是次世代定序（NGS），彻底改变了基因组学领域，提供了高通量、经济高效且更快的定序能力。 DNA定序与肿瘤学、遗传学和生殖健康等各研究领域的整合进一步加速了市场应用。单细胞定序、第三代定序技术等更先进、更精准的定序方法的发展，不断提升DNA定序的精确度和应用范围，使其成为临床诊断和个人化医疗中不可或缺的工具。

市场概况
预测期 2026-2030
2024 年市场规模 152.2 亿美元
2030 年市场规模 467.2 亿美元
2025-2030 年复合年增长率 20.53%
成长最快的领域 第三代定序
最大的市场 北美洲

DNA 定序市场的主要成长动力包括全球遗传疾病、癌症和其他慢性疾病的盛行率上升，以及政府对基因组研究的资助和措施增加。精准医疗的需求是推动市场扩张的重要因素，精准医疗需要详细的基因资讯来为个别患者制定治疗方案。此外，对早期疾病检测、药物开发和个人化治疗的需求日益增长，推动了医院、诊所和研究机构采用 DNA 定序。增强的生物资讯工具有助于分析和解释复杂的定序资料，从而实现更准确的诊断和治疗发展，在促进市场成长方面发挥了关键作用。

然而，市场面临着与先进测序技术相关的高成本的挑战，这可能会限制某些地区和小型医疗保健提供者的可及性。定序资料的复杂性以及解释结果的专业知识的要求带来了额外的障碍。此外，围绕基因组资料的伦理问题，包括隐私和基因资讯的潜在滥用，仍有争议。随着市场的扩大，透过开发更实惠的定序技术、改进的资料解释工具和更清晰的监管框架来应对这些挑战，以确保合乎道德和负责任地使用基因组信息，将至关重要。儘管有这些挑战，DNA定序在肿瘤学、个人化医疗和基因筛检等领域的广泛应用为未来市场成长提供了巨大的机会。

主要市场驱动因素

遗传疾病和癌症发生率不断上升

2021年，全球患有镰状细胞疾病的人数比2000年增加了41.4%，达到约774万人。

亨丁顿舞蹈症虽然较为罕见，但全球盛行率已上升至每十万人 4.88 人。

基因组研究和应用的扩展

例如，2022年12月，英国政府宣布投资2.1937亿美元用于基因组学研究，旨在打造世界上最先进的基因组医疗保健系统。

定序技术的进步

主要市场挑战

定序技术成本高昂

道德、法律和隐私问题

主要市场趋势

个人化和精准医疗

基因筛检应用增多

分段洞察

产品类型洞察

应用程式洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球 DNA 定序市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依产品类型（仪器、耗材、服务）
    • 按技术分类（桑格定序、次世代定序 (NGS)、第三代定序、其他）
    • 按应用（诊断、研究、个人化医疗、法医检测、其他）
    • 按最终用户（医院和医疗机构、学术和研究机构、製药和生物技术公司等）
    • 按公司分类（2024）
    • 按地区
  • 市场地图

第 6 章：北美 DNA 定序市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 墨西哥
    • 加拿大

第 7 章：欧洲 DNA 定序市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区 DNA 定序市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美 DNA 定序市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲 DNA 定序市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如果有）
  • 最新动态

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • QIAGEN NV
  • Merck KGaA
  • Macrogen, Inc.
  • PerkinElmer, Inc.
  • Eurofins Scientific Limited

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 27580

Global DNA Sequencing Market was valued at USD 15.22 Billion in 2024 and is expected to reach USD 46.72 Billion in the forecast period with a CAGR of 20.53% through 2030. The Global DNA Sequencing Market has experienced remarkable growth due to technological advancements, increasing applications in genomics, and rising demand for precision medicine. Sequencing technologies, particularly Next-Generation Sequencing (NGS), have revolutionized the field of genomics, offering high-throughput, cost-effective, and faster sequencing capabilities. The integration of DNA sequencing into various research domains such as oncology, genetics, and reproductive health has further accelerated market adoption. The development of more advanced and accurate sequencing methods, such as single-cell sequencing and third-generation sequencing technologies, continues to enhance the precision and applications of DNA sequencing, making it an indispensable tool in clinical diagnostics and personalized healthcare.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 15.22 Billion
Market Size 2030USD 46.72 Billion
CAGR 2025-203020.53%
Fastest Growing SegmentThird-Generation Sequencing
Largest MarketNorth America

Key growth drivers for the DNA sequencing market include the rising global prevalence of genetic disorders, cancer, and other chronic diseases, as well as increased government funding and initiatives for genomic research. The demand for precision medicine, which requires detailed genetic information to tailor treatments to individual patients, is a significant factor contributing to market expansion. Furthermore, the growing need for early disease detection, drug development, and personalized therapies has propelled the adoption of DNA sequencing across hospitals, clinics, and research institutions. Enhanced bioinformatics tools that help in analyzing and interpreting complex sequencing data have also played a crucial role in facilitating the market's growth by enabling more accurate diagnostics and therapeutic development.

However, the market faces challenges related to the high costs associated with advanced sequencing technologies, which can limit accessibility in certain regions and for smaller healthcare providers. The complexity of sequencing data and the requirement for specialized expertise to interpret results pose additional hurdles. Furthermore, ethical concerns surrounding genomic data, including privacy and the potential misuse of genetic information, continue to be debated. As the market expands, it will be crucial to address these challenges through the development of more affordable sequencing technologies, improved data interpretation tools, and clearer regulatory frameworks to ensure ethical and responsible use of genomic information. Despite these challenges, the expanding use of DNA sequencing in areas like oncology, personalized medicine, and genetic screening offers significant opportunities for future market growth.

Key Market Drivers

Increasing Incidence of Genetic Disorders and Cancer

The increasing incidence of genetic disorders and cancer is a significant driver for the Global DNA Sequencing Market. Genetic disorders, such as cystic fibrosis, sickle cell anemia, and Huntington's disease, affect millions worldwide. For instance, the World Health Organization estimates that 10 out of every 1,000 people are affected by genetic disorders, translating to between 70 million and 80 million individuals globally.

In 2021, the number of people living with sickle cell disease globally increased by 41.4% from 2000, reaching approximately 7.74 million.

Huntington's disease, though rarer, has seen a pooled global prevalence rise to 4.88 per 100,000 individuals.

Cancer prevalence has also escalated, with the World Health Organization reporting approximately 19.3 million new cancer cases and 10 million cancer-related deaths worldwide in 2020. This rising burden underscores the need for advanced diagnostic tools. DNA sequencing enables the identification of genetic mutations associated with various cancers, facilitating early detection and personalized treatment strategies. The growing recognition of the genetic underpinnings of many cancers has led to increased adoption of sequencing technologies in oncology.

The rising prevalence of these conditions has heightened the demand for DNA sequencing technologies, which are instrumental in diagnosing genetic disorders and informing targeted cancer therapies. As awareness of the genetic basis of diseases grows, healthcare providers are increasingly integrating sequencing into clinical practice to enhance patient outcomes. Consequently, the escalating incidence of genetic disorders and cancer is a pivotal factor propelling the expansion of the DNA sequencing market.

Expansion of Genomic Research and Applications

The expansion of genomic research and its growing applications across various sectors are driving the growth of the Global DNA Sequencing Market. Advances in next-generation sequencing (NGS) technologies have made it possible to decode genetic information faster, more accurately, and at a lower cost, enabling a wide range of applications in healthcare, agriculture, forensic science, and biotechnology. Governments and private organizations are heavily investing in genomic research initiatives to better understand genetic diseases, develop targeted therapies, and advance precision medicine. Large-scale projects such as the Human Genome Project and national genome sequencing initiatives have created significant momentum in the adoption of sequencing technologies.

In healthcare, the increasing focus on personalized medicine and pharmacogenomics has fueled demand for DNA sequencing in diagnosing genetic disorders, predicting disease susceptibility, and optimizing treatment strategies. The integration of sequencing with artificial intelligence and bioinformatics has enhanced the interpretation of genetic data, leading to more precise insights into disease mechanisms and drug responses. The use of DNA sequencing in oncology for cancer profiling and treatment selection has further strengthened its role in clinical settings.

Beyond healthcare, DNA sequencing is playing a crucial role in agriculture and food safety by enabling the development of genetically modified crops, improving disease resistance, and enhancing food traceability. In forensic science, sequencing is aiding in criminal investigations, ancestry determination, and disaster victim identification. With continuous advancements in sequencing platforms, declining costs, and increasing government and private sector investments, the applications of DNA sequencing are expected to expand further, making genomic research a key driver of market growth.

For instance, in December 2022, the UK government announced a USD 219.37 million investment in genomics research, aiming to create the most advanced genomic healthcare system in the world.

Similarly, the U.S. National Institutes of Health (NIH) allocated USD 320.4 million for Research Project Grants (RPGs) in fiscal year 2023, supporting a total of 414 awards, including those related to genomic research. These substantial investments underscore the commitment to advancing genomic research and its applications, further propelling the growth of the DNA sequencing market.

Technological Advancements in Sequencing Technologies

Technological advancements in sequencing technologies have significantly accelerated the growth of the Global DNA Sequencing Market. The evolution from traditional sequencing methods to more advanced platforms, such as Next-Generation Sequencing (NGS) and Third-Generation Sequencing, has enabled faster, more accurate, and cost-effective analysis of genomes. These innovations have substantially increased the throughput and scalability of sequencing, making it more accessible to a wider range of applications, including clinical diagnostics, research, and personalized medicine.

NGS technologies, for instance, allow researchers to sequence entire genomes or targeted regions with high accuracy and at a fraction of the cost compared to earlier methods like Sanger sequencing. As a result, NGS has become a vital tool in understanding genetic disorders, detecting rare diseases, and identifying biomarkers for drug development. The reduction in sequencing costs, driven by advancements such as illumina sequencing and single-molecule real-time sequencing, has made it possible for healthcare systems, academic institutions, and research laboratories to implement DNA sequencing on a broader scale.

Additionally, the development of more advanced data analysis software and algorithms has improved the ability to interpret complex genomic data. These innovations have expanded the potential of DNA sequencing beyond traditional applications, supporting the rise of precision medicine, where treatments are tailored based on individual genetic profiles. As sequencing technologies continue to evolve, they offer greater speed, accuracy, and efficiency, driving significant demand in various sectors, including diagnostics, pharmaceuticals, and biotechnology. This continuous innovation is a key driver for the global DNA sequencing market, with ongoing advancements expected to further enhance its capabilities and applications.

Key Market Challenges

High Costs of Sequencing Technologies

The Global DNA Sequencing Market faces several challenges, notably the high costs associated with sequencing technologies. Despite significant advancements, the expense of sequencing remains a substantial barrier to widespread adoption, particularly in resource-constrained settings. For instance, while the cost of sequencing a human genome has decreased from approximately USD 3 billion during the Human Genome Project to around USD 600 in recent years, it still represents a significant investment for many institutions and healthcare providers.

The high costs are attributed to several factors, including the need for specialized equipment, consumables, and skilled personnel. Next-Generation Sequencing (NGS) platforms, which offer high throughput and accuracy, require substantial initial investment and ongoing maintenance expenses. Additionally, the complexity of data analysis necessitates advanced computational resources and expertise, further increasing the overall cost of sequencing projects.

These financial barriers limit the accessibility of DNA sequencing technologies, particularly in developing regions and smaller research institutions. The disparity in access to advanced sequencing technologies can hinder global efforts in genomics research, personalized medicine, and the development of targeted therapies. Addressing the high costs associated with sequencing technologies is crucial to ensure equitable access to genomic advancements and to fully realize the potential benefits of DNA sequencing in healthcare and research.

Ethical, Legal, and Privacy Concerns

Ethical, legal, and privacy concerns represent a significant challenge in the Global DNA Sequencing Market. The increasing adoption of DNA sequencing technologies in healthcare and research has raised questions about how genetic data is collected, stored, and shared. One of the primary concerns revolves around data privacy, as DNA contains highly personal and sensitive information. Unauthorized access or breaches in data security could lead to the misuse of genetic data, compromising individuals' privacy and confidentiality. Regulatory frameworks governing data storage and usage are still evolving, and this lack of consistency and clear regulations increases uncertainty for stakeholders in the market.

The ethical issues surrounding DNA sequencing are complex. There is growing concern over the potential for genetic information to be used for purposes beyond healthcare, such as insurance discrimination or employment bias. The ability to predict genetic diseases may also create ethical dilemmas about pre-emptive testing, especially when it comes to minors or individuals without symptoms. The notion of genetic modification or altering genetic material in embryos also raises moral questions about the extent of intervention in natural biological processes.

Legal challenges also persist in the form of intellectual property rights, consent procedures, and ownership of genetic data. With numerous entities involved in sequencing and analyzing genetic data, clarifying who holds the rights to genetic information is increasingly important. Countries and regions have varying regulations regarding genetic data use, and aligning international standards is difficult. These ethical, legal, and privacy concerns could hinder the widespread adoption of DNA sequencing technologies and delay further advancements in genomics.

Key Market Trends

Personalized and Precision Medicine

The trend of Personalized and Precision Medicine is significantly transforming the Global DNA Sequencing Market. Personalized and precision medicine involve tailoring medical treatment to individual characteristics, such as genetic makeup, lifestyle, and environment. DNA sequencing plays a pivotal role in this approach by providing detailed genetic information, which helps in understanding how an individual's unique genetic profile can influence their response to treatments and susceptibility to diseases. This trend is increasingly becoming central to the healthcare landscape as it allows for more effective and targeted therapies, particularly in oncology, cardiology, and rare genetic disorders.

With advancements in Next-Generation Sequencing (NGS) technologies, it has become more affordable and accessible to integrate genetic data into clinical practice. DNA sequencing enables clinicians to identify genetic mutations that may not be apparent through traditional diagnostic methods, improving early detection and the ability to predict health risks with greater accuracy. This ability to identify genetic predispositions is especially valuable in diseases like cancer, where understanding mutations allows for the development of customized treatment plans that are more likely to succeed.

The adoption of personalized medicine is also being driven by an increasing focus on improving patient outcomes and reducing healthcare costs. By identifying the most effective treatment options based on an individual's genetic makeup, unnecessary treatments can be avoided, leading to more efficient use of healthcare resources. As awareness of the benefits of personalized healthcare continues to grow, the demand for DNA sequencing technologies will rise, making it one of the key trends influencing the market's expansion in the coming years.

Increased Use in Genetic Screening

The increased use of DNA sequencing in genetic screening is one of the prominent trends driving growth in the Global DNA Sequencing Market. Genetic screening involves analyzing an individual's DNA to detect genetic disorders, inherited conditions, and predispositions to diseases, playing a vital role in early disease detection and prevention. As awareness of genetic risks and personalized medicine increases, more individuals are seeking genetic testing to understand their potential health risks, prompting healthcare providers to incorporate DNA sequencing as a key diagnostic tool.

This trend is particularly significant in oncology, where DNA sequencing is used to identify genetic mutations associated with cancer risk and to guide treatment decisions. It also has applications in prenatal screening, carrier screening for genetic disorders, and pharmacogenomics, which helps in determining the most effective medications based on an individual's genetic makeup. As the cost of DNA sequencing continues to decrease and technologies like Next-Generation Sequencing (NGS) become more accessible, genetic screening is no longer limited to research settings and is increasingly offered as a routine diagnostic tool in clinical practices.

The growing emphasis on preventive healthcare and personalized medicine is contributing to the expansion of genetic screening. As healthcare systems worldwide seek more effective ways to manage long-term diseases and reduce healthcare costs, early detection of genetic risks allows for timely interventions, improving patient outcomes. The ability to offer personalized treatment plans based on genetic data is also driving demand for DNA sequencing in clinical genetic screening. This trend is expected to continue gaining momentum, further establishing DNA sequencing as a cornerstone in modern healthcare and diagnostics.

Segmental Insights

Product Type Insights

Based on the Product Type, Consumables emerged as the dominant segment in the Global DNA Sequencing Market in 2024. This is due to several key factors. Consumables such as reagents, chemicals, and kits are essential components required for the DNA sequencing process. These consumables are used repeatedly across various sequencing workflows, making them a consistent source of revenue in the market. As the demand for DNA sequencing services continues to rise, the need for consumables increases, particularly in research and clinical settings where sequencing is increasingly integrated into diagnostics and personalized medicine. The widespread adoption of Next-Generation Sequencing (NGS) technologies has further fueled the demand for consumables. NGS relies on a range of high-quality consumables, such as sequencing primers, probes, and adapters, to perform sequencing reactions accurately and efficiently. Additionally, the growth of genomic research and clinical applications such as cancer genomics, genetic screening, and precision medicine has contributed to the substantial demand for consumables. These consumables are necessary for maintaining the high throughput, accuracy, and reliability of sequencing platforms, making them integral to the DNA sequencing process. As a result, the consumables segment is expected to continue dominating the market, driven by their essential role in the sequencing process and the increasing number of sequencing applications globally.

Application Insights

Based on the Application, Diagnostics emerged as the dominant segment in the Global DNA Sequencing Market in 2024. This is due to the growing importance of genetic testing in disease detection, personalized medicine, and early diagnosis. DNA sequencing plays a critical role in identifying genetic mutations, abnormalities, and predispositions that can lead to various health conditions, including cancer, genetic disorders, and infectious diseases. The increased adoption of DNA sequencing in clinical diagnostics has made it an invaluable tool for improving patient care, providing more accurate diagnoses, and enabling the development of tailored treatment plans. Advancements in sequencing technologies, such as Next-Generation Sequencing (NGS), have made genetic testing more accessible, affordable, and efficient, further driving the growth of the diagnostics segment. Additionally, the growing emphasis on personalized medicine, which relies on genetic data to determine the best course of treatment for individuals, has further boosted the demand for DNA sequencing in diagnostic applications. With DNA sequencing offering the ability to analyze entire genomes or targeted genetic regions, it is increasingly being utilized in oncology for tumor profiling, pharmacogenomics for drug response prediction, and rare genetic disease diagnosis. The ability of DNA sequencing to provide precise and actionable insights into an individual's health is making it the dominant application in the market, with expanding use cases in clinical diagnostics globally.

Regional Insights

North America emerged as the dominant region in the Global DNA Sequencing Market in 2024. This is due to several key factors. The region benefits from advanced healthcare infrastructure, strong research and development activities, and a high level of investment in genomics and biotechnology. The presence of major players in the DNA sequencing market, such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences, has established North America as a hub for innovation in sequencing technologies. Additionally, the growing demand for personalized medicine, precision diagnostics, and genomic research has further contributed to the market's expansion in the region. The robust healthcare system in North America, especially in the United States, has facilitated the adoption of DNA sequencing technologies across clinical settings. DNA sequencing is increasingly used in diagnostics, oncology, genetic testing, and pharmacogenomics, leading to higher demand in both research and healthcare applications. Furthermore, the strong emphasis on personalized medicine and the growing number of government initiatives and funding for genomic research are driving market growth in the region. The regulatory environment in North America, which supports the approval and commercialization of new genomic technologies, also plays a crucial role in maintaining the region's dominance in the DNA sequencing market. These factors combined have made North America the leading region in the global market in 2024.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Merck KGaA
  • Macrogen, Inc.
  • PerkinElmer, Inc.
  • Eurofins Scientific Limited

Report Scope:

In this report, the Global DNA Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Sequencing Market, By Product Type:

  • Instruments
  • Consumables
  • Services

DNA Sequencing Market, By Technology:

  • Sanger Sequencing
  • Next-Generation Sequencing (NGS)
  • Third-Generation Sequencing
  • Others

DNA Sequencing Market, By Application:

  • Diagnostics
  • Research
  • Personalized Medicine
  • Forensic Testing
  • Others

DNA Sequencing Market, By End User:

  • Hospitals and Healthcare Organizations
  • Academics and Research Institutions
  • Pharmaceutical and Biotechnology Companies
  • Others

DNA Sequencing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Sequencing Market.

Available Customizations:

Global DNA Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global DNA Sequencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Instruments, Consumables, Services)
    • 5.2.2. By Technology (Sanger Sequencing, Next-Generation Sequencing (NGS), Third-Generation Sequencing, Others)
    • 5.2.3. By Application (Diagnostics, Research, Personalized Medicine, Forensic Testing, Others)
    • 5.2.4. By End User (Hospitals and Healthcare Organizations, Academics and Research Institutions, Pharmaceutical and Biotechnology Companies, Others)
    • 5.2.5. By Company (2024)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America DNA Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States DNA Sequencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Mexico DNA Sequencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Canada DNA Sequencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe DNA Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France DNA Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany DNA Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom DNA Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy DNA Sequencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain DNA Sequencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific DNA Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China DNA Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India DNA Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. South Korea DNA Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Japan DNA Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia DNA Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America DNA Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil DNA Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina DNA Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia DNA Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa DNA Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa DNA Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia DNA Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE DNA Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Thermo Fisher Scientific Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Agilent Technologies, Inc.
  • 14.3. Bio-Rad Laboratories, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd.
  • 14.5. Illumina, Inc.
  • 14.6. QIAGEN N.V.
  • 14.7. Merck KGaA
  • 14.8. Macrogen, Inc.
  • 14.9. PerkinElmer, Inc.
  • 14.10. Eurofins Scientific Limited

15. Strategic Recommendations

16. About Us & Disclaimer